- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Volume is elevated versus the 13-week average, confirming attention.
TNGX
NASDAQ
Week ended 25 Sep 2026
Weekly Investor Report
Tango Therapeutics Inc · Healthcare · Biotechnology
Latest close
24.92 USD
14.6%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is 3.8% above the Trend Line and sits at 65.8% of its 52-week range. The latest completed week returned 14.6%, after a 6.8% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is bearish with 55/100 conviction, while the latest news-sentiment score is 49/100. Near-term considerations: earnings are due in 37d.
Setup score
51
out of 100
Latest Close
24.92 USD
25 Sep 2026
1W Return
14.6%
latest completed week
4W Return
6.8%
short-term follow-through
12W Return
-15.4%
quarterly tape
Trend Breadth
96.2%
50 of 52 weeks active
Volume Ratio
1.6x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Activity pressure is negative, which weakens the current setup.
- Next-week expectancy is negative at 44.03% based on similar historical setup states.
- The share remains more than 20% below its 52-week high.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
14.6%
Latest completed week; four-week move 6.8%.
Indicator stack
53/30
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 44.03%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
Options pressure
Bearish
55/100 conviction; expected move 0.0%.
News sentiment
49/100
13 relevant articles in the latest sentiment read.
Event risk
37d
Next report is scheduled for 03 Nov 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is 3.8% above the Trend Line and sits at 65.8% of its 52-week range. The latest completed week returned 14.6%, after a 6.8% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 1.6x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
14 Aug
21 Aug
28 Aug
4 Sep
11 Sep
18 Sep
25 Sep
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.5412-week average 0.75
12-week confirmation
Trend active10/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure3/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.54Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 6.8% over four weeks, -15.4% over 12 weeks, and 192.1% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year50
Trend breadth96.2%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-1.05Latest activity-pressure read.
Pressure change-9.1%Four-week change in activity pressure.
Leadership23.73Latest relative-leadership reading.
RS change-14.1%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 18 Sep 2026
Financial statements through 30 Jun 2026
Field coverage 79%
Model confidence 79%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength36/100Blend of value, momentum, and quality. Underlying universe rank 65; rank 1 is best.
Value44/100Relative valuation strength. Underlying universe rank 57; rank 1 is best.
Quality41/100Profitability and accounting quality. Underlying universe rank 60; rank 1 is best.
Momentum43/100Medium-term price momentum. Underlying universe rank 58; rank 1 is best.
Growth42/100Revenue and earnings growth. Underlying universe rank 59; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 68.2x Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -4.3% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- - Gross profit retained from each unit of revenue.
- Operating margin
- -253.4% Operating profit retained from revenue.
- Free-cash-flow margin
- -268.1% Free cash flow generated from revenue.
- Return on invested capital
- -14.4% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 121.5% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 4/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -25.3% Net share repurchases relative to market value.
- Shareholder yield
- -25.3% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 2.3x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Options positioningBearish
TNGX shows bearish options pressure with a 55/100 conviction score, put-call volume ratio of 10.75, expected move of n/a, and Sharemaestro trend signal inactive.
Conviction55/100
Expected move%
Put/call volume10.75
Insider activity12 / 8
12 acquisitions and 8 disposals in the latest 180-day insider tape.
Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.News sentiment49/100
Weighted news tone is neutral across 13 relevant articles.
0 positive · 7 neutral · 6 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings37dNext report is scheduled for 03 Nov 2026; event risk rises as the date approaches.
Options expected move%Nearest-chain priced movement where available.
52-week drawdown-27.5%Distance below the 52-week high.
13-week volatility6.6%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
3 Apr
1 May
29 May
26 Jun
24 Jul
21 Aug
25 Sep
Weeks higher10 of 2616 weeks finished lower.
Best week+53.0%Week of 12 Jun.
Worst week-18.6%Week of 1 May.
Latest week+14.6%Week of 25 Sep.
Shape of recent returns
Strong gains9
Modest gains1
Flat weeks0
Modest losses5
Sharp losses11
Recent vol6.6%13-week weekly-return volatility.
Base vol14.9%52-week weekly-return volatility.
Up/down split24/28Count of positive and negative weeks in the 52-week window.
Average skew14.7% / -6.9%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average-0.4%
Trend breadth67.0%
Trend67.0%active weekly trend signals
MD63.0%positive activity pressure
RS50.0%positive relative leadership
Four-week leaders
IndustryUS Biotechnology
4-week rank15 / 100
Group average-5.5%
Trend breadth70.0%
Trend70.0%active weekly trend signals
MD52.0%positive activity pressure
RS45.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape51/100
Trend, activity pressure, participation, and risk combine to a 51/100 tape read.
Indicator analysis63/100Latest 12-week confirmation: trend 10/12, activity pressure 3/12, relative leadership 12/12.
Activity pressure 0.54; No reversal markers Next-Week ExpectancyNegative 44.03%Next-week expectancy is negative with a 44.03% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors40/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 95; Small Cap Core rank 59 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Options31/100Put activity leads. Options balance does not yet confirm the saved weekly stock trend.
2026-09-24 · Use with limits · Priced move Unavailable Sentiment49/100Weighted news tone is neutral across 13 relevant articles.
Officer at Tango Therapeutics (NASDAQ: TNGX) to sell 15K shares Insiders12 / 812 acquisitions and 8 disposals in the latest 180-day insider tape.
Earnings37dNext report is scheduled for 03 Nov 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 25 Sep 2026 | 24.92 USD | 14.6% | 24.00 USD | 10.45 USD | -1.05 | 23.73 | 20.0M | Off |
| 18 Sep 2026 | 21.75 USD | -8.5% | 23.54 USD | 10.36 USD | -1.17 | 13.09 | 14.6M | Off |
| 11 Sep 2026 | 23.78 USD | 5.6% | 23.22 USD | 10.29 USD | -1.17 | 26.37 | 12.8M | On |
| 4 Sep 2026 | 22.52 USD | -3.5% | 22.86 USD | 10.19 USD | -1.17 | 20.95 | 8.1M | On |
| 28 Aug 2026 | 23.34 USD | -2.3% | 22.53 USD | 10.09 USD | -0.96 | 27.62 | 11.6M | On |
| 21 Aug 2026 | 23.88 USD | -6.7% | 22.14 USD | 9.99 USD | -0.77 | 33.20 | 10.9M | On |
| 14 Aug 2026 | 25.60 USD | -5.4% | 21.73 USD | 9.88 USD | -0.60 | 41.52 | 10.9M | On |
| 7 Aug 2026 | 27.07 USD | -0.4% | 21.31 USD | 9.76 USD | -0.35 | 54.10 | 10.3M | On |
| 31 Jul 2026 | 27.18 USD | 2.1% | 20.80 USD | 9.63 USD | -0.14 | 66.01 | 14.1M | On |
| 24 Jul 2026 | 26.63 USD | -6.8% | 20.19 USD | 9.48 USD | 0.08 | 67.28 | 8.3M | On |
| 17 Jul 2026 | 28.56 USD | -8.0% | 19.59 USD | 9.33 USD | 0.44 | 80.55 | 12.7M | On |
| 10 Jul 2026 | 31.06 USD | 5.4% | 18.93 USD | 9.17 USD | 0.55 | 92.91 | 15.0M | On |
| 3 Jul 2026 | 29.46 USD | -6.4% | 18.20 USD | 8.99 USD | 0.70 | 91.61 | 17.3M | On |
| 26 Jun 2026 | 31.47 USD | 12.5% | 17.54 USD | 8.82 USD | 0.49 | 112.32 | 36.4M | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.